This year, The Business of Biosimilars event is expanding to the Business of Biosimilars and Biobetters in order to better address the needs of our audience and reflect the changes in the biopharmaceutical industry. Due to the
lack of regulatory guidance within the US and the ongoing debate about the anticipated value of commercializing biosimilars in the US and abroad, we have decided to expand the scope of our meeting to enable pharmaceutical and biotech companies to discover global biosimilar and biobetter commercialization opportunities through in depth analysis of scientific and business development considerations.